Novel agents and new therapeutic approaches for treatment of multiple myeloma.

摘要: This review summarizes the therapeutic strategies and drugs actually in development for management of myeloma patients. Multiple is caused by expansion monoclonal plasma cells secretion M-protein (immunoglobulins, Bence Jones protein free light chains). still remains an incurable disease with a high incidence rate elderly, despite introduction several new agents (bortezomib, lenalidomide thalidomide) which have changed its natural history. The heterogeneity this leads to large differences clinical responses treatments. Thus, choice best treatment difficult issue. However, has made it possible achieve response rates good quality long-term control. Interactions between tumor their bone marrow microenvironment play pivotal role development, maintenance, progression myeloma, inducing also drug resistance. These knowledges improved options, leading approval not only target malignant cell itself, but microenvironment. are preclinical/early evaluation they appear further improve control, use approved outside trials.